Mereo BioPharma Group
NASDAQ: MREOLondon, GB · Founded 2015 · Incorporated in United Kingdom · 43 employees on LinkedIn · 3 known investors
Mereo BioPharma is a biopharmaceutical company publicly traded on Nasdaq under the ticker MREO. This page presents its share price data and SEC filings for investors and commercial partners.
Founders & leadership
Mereo BioPharma Group was founded in 2015 by John Richard and Charles Sermon.
JR
John RichardinHead of Corporate Development and Co-Founder
CS
Charles SermonGeneral Counsel and Co-Founder
RJ
Richard JonesinChief Financial Officer
JH
Jill HenrichinSenior Vice President
DS
Denise Scots-KnightinChief Executive Officer
Board
DD
Dr. Deepa PakianathanNon-Executive Director
DP
Dr. Peter FellnerChairman
KK
Kunal KashyapNon-Executive Director
PB
Paul BlackburnNon-Executive Director
PB
Peter BainsNon-Executive Director
MW
Michael WyzgaNon-Executive Director
DA
Dr. Anders EkblomNon-Executive Director
Investors · 3
Reported raises · per SEC filings
Form D private placements$70M disclosed across 1 round · 2020
▶$70MraisedJun 2020 · 25 investors · PharmaceuticalsRule 506(b)
▶$70MraisedJun 2020 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Peter FellnerDirector
- Richard JonesExecutive Officer, Director
- Kunal KashyapDirector
- Paul BlackburnDirector
- John RichardExecutive Officer
- Dr. Denise Scots-KnightExecutive Officer, Director
- Jill HenrichExecutive Officer
- Charles SermonExecutive Officer
- Peter BainsDirector
- Michael WyzgaDirector
- Dr. Anders EkblomDirector
- Dr. Deepa PakianathanDirector
- Dr. Alastair MacKinnonExecutive Officer
- Offering amount
- $70M
- Amount sold
- $70M
- Minimum investment
- $1
- Sales commissions
- $4.2M
- Placement agents
- SVB Leerink LLC
- First sale
- Jun 2020
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld67 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eli Lilly52 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Companies competing with Mereo BioPharma Group for the same Google search keywords, organic and paid, via search-intersection analysis.
Companies House · registry record
View on Companies House ↗- Registered name
- MEREO BIOPHARMA GROUP PLC
- Company number
- 09481161
- Status
- Active
- Company type
- Public limited company
- Incorporated
- 10 Mar 2015
- Registered office
- 4th Floor, One, Cavendish Place, London, W1G 0QF
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Previous names
- MEREO BIOPHARMA GROUP LIMITED (2015–2016)
- Accounts
- last made up to 31 Dec 2025 · next due 30 Jun 2027
- Confirmation statement
- last made up to 23 Feb 2026 · next due 9 Mar 2027
Current officers · 10
- Charles Edward Sermon — secretary, appointed 9 Nov 2023
- Jeremy Bender — director, appointed 1 Oct 2020
- Anders Ekblom — director, appointed 21 Apr 2015
- Pierre Jacquet — director, appointed 20 Sept 2021
- Deepika Pakianathan — director, appointed 23 Apr 2019
- Justin Roberts — director, appointed 10 Nov 2022
- Denise Vera Scots-Knight — director, appointed 10 Mar 2015
- Daniel Shames — director, appointed 10 Nov 2022
- Michael Wyzga — director, appointed 23 Apr 2019
- Marc Yoskowitz — director, appointed 10 Nov 2022
Source: Companies House public register · retrieved 13 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Mereo BioPharma Group plc Q2 2026: Revenue $0 Net loss $7.01M, EPS $(0.01) — 10-Q Summarytradingview.com · Aug 2026Frequently asked questions
- What does Mereo BioPharma Group do?
- Mereo BioPharma is a biopharmaceutical company publicly traded on Nasdaq under the ticker MREO. This page presents its share price data and SEC filings for investors and commercial partners.
- Who founded Mereo BioPharma Group?
- Mereo BioPharma Group was founded by John Richard, Charles Sermon in 2015.
- Who are Mereo BioPharma Group's investors?
- Mereo BioPharma Group's investors include Pontifax Venture Capital, Vivo Capital, Woodford Investment Management.
- How much funding has Mereo BioPharma Group raised?
- Mereo BioPharma Group has disclosed $70M raised across 1 round.
- Where is Mereo BioPharma Group headquartered?
- Mereo BioPharma Group is headquartered in London, GB.